Sage Therapeutics and partner Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

April 29, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors. In terms of prescriber ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen ... remains ongoing Sage Therapeutics, Inc ...

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today reported ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors.

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics and partner Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan, ...

Welcome to Sage Therapeutics First Quarter 2025 Financial ... which represents 50% of the net revenue recorded by Biogen, a 21% increase from the fourth quarter of 2024. Importantly, we are ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...